. 2020 Jun 5;20(2):2028–2034. doi: 10.3892/ol.2020.11705

Table IV.

Comparison of expression levels of serum CA125, VEGF and OPN in different clinicopathological factors of ovarian cancer (mean ± SD).

Variables	Cases	CA125 (U/ml)	t-test	P-value	VEGF (pg/ml)	t-test	P-value	OPN (ng/ml)	t-test	P-value
Clinical stage
Stage I+II	50	121.68±17.63	2.590	0.041	553.26±45.37	3.286	0.017	125.48±14.82	4.680	0.003
Stage III+IV	56	213.65±35.32^a			792.22±65.61^a			298.24±38.67^a
Differentiation degree	58
Well and middle		115.52±22.68.	3.116	0.021	493.25±36.54	5.119	0.002	135.69±15.67	4.421	0.004
Poor	48	235.85±36.54^a			865.31±71.24^a			315.26±42.85^a
Ascites
No	42	110.59±13.11	3.194	0.019	567.28±43.29	2.671	0.037	142.69±20.81	3.737	0.010
Yes	64	208.65±31.37^a			753.62±63.55^a			265.87±36.39^a
Lymph node metastasis
No	39	99.84±18.30	3.161	0.020	530.29±37.26	3.228	0.018	148.52±16.87	3.074	0.022
Yes	67	210.28±34.31^a			766.35±71.41^a			256.74±35.12^a
Distant metastasis
No	94	138.42±17.31	5.302	0.002	559.25±37.70	6.932	<0.001	122.35±17.41	6.013	<0.001
Yes	12	412.35±54.01^a			1,623.65±108.71^a			546.92±54.05^a
Recurrence
No	81	39.87±8.81	8.076	<0.001	153.21±19.82	8.367	<0.001	56.82±11.18	9.125	<0.001
Yes	25	423.86±52.41^a			1,365.02±79.51^a			436.82±41.27^a
Treatment
Before	106	169.82±26.38^a	5.330	0.002	679.62±57.83^a	9.214	<0.001	216.87±34.95^a	4.558	0.004
After	106	41.27±10.67			162.36±23.06			65.01±12.25

P<0.05, comparison within the group. CA125, carbohydrate antigen 125; VEGF, vascular endothelial growth factor; OPN, osteopontin.